Sunday, October 01, 2006
If Less is More, Just Imagine How Much More is More!
The best cure for the body is a quiet mind.
Meropenem is a medication that I have been on twice now as part of my IV tune-up regimen. By itself I don't think it would be completely sufficient for knocking out the types of infections I get (PA, B. cepacia and the like) but its synergistic effects when combined with medications like Tobra or Colistin make it pretty powerful.
Meropenem, commonly referred to as Merrem, is the first carbapenem to be approved for use in the United States and others are sure to follow. A recently published article about a study carried out by Johnson & Johnson Pharmaceuticals highlights the findings of yet another, more powerful carbapenem (Doripenem) that may soon be available. If Merrem is good, is this new one even better? As is usually the case for us CFers awaiting new and better treatments, one can only hope.
Read the original article as it appears here
--Napoleon Bonaparte
Meropenem is a medication that I have been on twice now as part of my IV tune-up regimen. By itself I don't think it would be completely sufficient for knocking out the types of infections I get (PA, B. cepacia and the like) but its synergistic effects when combined with medications like Tobra or Colistin make it pretty powerful.
Meropenem, commonly referred to as Merrem, is the first carbapenem to be approved for use in the United States and others are sure to follow. A recently published article about a study carried out by Johnson & Johnson Pharmaceuticals highlights the findings of yet another, more powerful carbapenem (Doripenem) that may soon be available. If Merrem is good, is this new one even better? As is usually the case for us CFers awaiting new and better treatments, one can only hope.
SAN FRANCISCO, Sept. 29 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research and Development, L.L.C. today announced that doripenem, an investigational carbapenem(1) antibiotic in Phase III trials, achieved a high clinical cure rate of 83 percent in patients with intra-abdominal infections. Doripenem also was active against a wide range of Gram-positive(2) and Gram-negative(3) bacteria that cause serious hospital infections -- including Pseudomonas.
Read the original article as it appears here
